Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8524350 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL8470100 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL8524354 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL8470094 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL1087799 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL5608101 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL9067679 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL7639529 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL9067686 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 | |
| SCHEMBL7639537 | 0.91 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2960164-B2 | — | — | 1999-10-06 | — | — | JP | claimed |
| EP-0560794-B1 | SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | IAF BIOCHEM INT (CA) | 1996-09-18 | — | — | EP | claimed |
| EP-0560794-A1 | SUBSTITUTED 1,3-OXATHIOLANES AND SUBSTITUTED 1,3-DITHIOLANES WITH ANTIVIRAL PROPERTIES. | IAF BIOCHEM INT (CA) | 1993-09-22 | — | — | EP | claimed |
| WO-1992008717-A1 | SUBSTITUTED 1,3-OXATHIOLANES AND SUBSTITUTED 1,3-DITHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1992-05-29 | — | — | WO | claimed |
| US-8354546-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes | Vertichem Corporation (CA) | 2013-01-15 | — | — | US | disclosed |
| US-20120157693-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | THESIS CHEMISTRY, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153416-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution | THESIS CHEMISTRY, LLC (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2010068756-A2 | PROCESS FOR MANUFACTURE OF OPTICALLY ACTIVE 2-(ACYLOXYMETHYL)-1, 3 OXATHIOLANES | THESIS CHEMISTRY, LLC (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100143978-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | THESIS CHEMISTRY, LLC (US) | 2010-06-10 | — | — | US | disclosed |
| EP-1473294-B1 | Substituted 1,3-oxathiolanes with antiviral properties | SHIRE BIOCHEM INC (CA) | 2007-04-18 | — | — | EP | disclosed |
| EP-1473294-A2 | Substituted 1,3-oxathiolanes with antiviral properties | Shire Biochem Inc. (CA) | 2004-11-03 | — | — | EP | disclosed |
| EP-1153924-B1 | Substituted 1,3-oxathiolanes with antiviral properties | SHIRE BIOCHEM INC (CA) | 2004-09-01 | — | — | EP | disclosed |
| EP-1153924-A2 | Substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC (CA) | 2001-11-14 | — | — | EP | disclosed |
| US-6228860-B1 | ADMINISTERING TO TREAT HUMAN IMMUNODEFICIENCY OR HEPATITIS VIRUS INFECTIONS IN MAMMALS RESISTANT TO 3TC OR FTC | BIOCHEM PHARMA INC. (CA) | 2001-05-08 | — | — | US | disclosed |
| EP-0756595-A1 | SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC (CA) | 1997-02-05 | — | — | EP | disclosed |
| US-5587480-A | TREATING HIV AND HEPATITIS VIRUS INFECTIONS | BIOCHEM PHARMA, INC. (CA) | 1996-12-24 | — | — | US | disclosed |
| EP-0560794-B1 | SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | IAF BIOCHEM INT (CA) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995029176-A1 | SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1995-11-02 | — | — | WO | disclosed |
| EP-0560794-A1 | SUBSTITUTED 1,3-OXATHIOLANES AND SUBSTITUTED 1,3-DITHIOLANES WITH ANTIVIRAL PROPERTIES. | IAF BIOCHEM INT (CA) | 1993-09-22 | — | — | EP | disclosed |
| WO-1992008717-A1 | SUBSTITUTED 1,3-OXATHIOLANES AND SUBSTITUTED 1,3-DITHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157693-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | APRT, TYMP, PNP | CHRNB2 4509/4885CHRNA5 3891/4885CHRNA7 3910/4885 |
| US-20100143978-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | APRT, TYMP, PNP | CHRNB2 4509/4885CHRNA5 3891/4885CHRNA7 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.